{"title":"Dynamics of Prolactin and Hormones of the Hypothalamic-Pituitary Thyroid Axis in Patients with Schizophrenia","authors":"L. N. Gorobets, A. V. Litvinov, V. S. Bulanov","doi":"10.1134/s1819712424010069","DOIUrl":null,"url":null,"abstract":"<p><b>Abstract</b>—In 70 examined patients, 34 with the first psychotic episode (FPE) and 36 with chronic schizophrenia (CS), we studied dynamics of the prolactin (PRL), thyroid-stimulating hormone (TSH), and free thyroxine (T<sub>4</sub>) during olanzapine therapy. Background hyperprolactinemia (HP) was observed in 52.9% of patients with FPE, which had with mean values of 971.1 ± 420 mIU/L, and in 50% of patients with CS (mean prolactin values were 1131 ± 845.4 mIU/L). In 11.8% of patients with FPE and in 16.6% of patients with CS, the level of free T<sub>4</sub> was below the standard values (mean values: 7.5 ± 0.3 pmol/L and 8.0 ± 0.8 pmol/L, respectively). TSH parameters in patients with FPE were within the reference values. Elevated background levels of TSH in patients with CS were observed in 11.1% of cases (4.8 ± 0.7 mIU/mL). By 6–8 weeks, an increase in mean PRL values was observed in all patients. Fluctuations in thyroid hormone levels by the end of therapy were insignificant. Four variants of dynamic changes in PRL and hypothalamic-pituitary-thyroid (HPT) axis hormones in patients during olanzapine therapy were identified. The relationship between PRL and thyroid hormones is discussed. The data obtained dictate the need to study the characteristics of the ratio of the levels of these hormones before the start of antipsychotic therapy (AT) in order to detect hypothyroidism and HP early, as well as to prevent the development of these hormonal dysfunctions in the process of AT and confirm the need to assess the levels of PRL and HPT-axis hormones in patients with FPE and CS before the start of the appointment of AT.</p>","PeriodicalId":19119,"journal":{"name":"Neurochemical Journal","volume":null,"pages":null},"PeriodicalIF":0.5000,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurochemical Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1134/s1819712424010069","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract—In 70 examined patients, 34 with the first psychotic episode (FPE) and 36 with chronic schizophrenia (CS), we studied dynamics of the prolactin (PRL), thyroid-stimulating hormone (TSH), and free thyroxine (T4) during olanzapine therapy. Background hyperprolactinemia (HP) was observed in 52.9% of patients with FPE, which had with mean values of 971.1 ± 420 mIU/L, and in 50% of patients with CS (mean prolactin values were 1131 ± 845.4 mIU/L). In 11.8% of patients with FPE and in 16.6% of patients with CS, the level of free T4 was below the standard values (mean values: 7.5 ± 0.3 pmol/L and 8.0 ± 0.8 pmol/L, respectively). TSH parameters in patients with FPE were within the reference values. Elevated background levels of TSH in patients with CS were observed in 11.1% of cases (4.8 ± 0.7 mIU/mL). By 6–8 weeks, an increase in mean PRL values was observed in all patients. Fluctuations in thyroid hormone levels by the end of therapy were insignificant. Four variants of dynamic changes in PRL and hypothalamic-pituitary-thyroid (HPT) axis hormones in patients during olanzapine therapy were identified. The relationship between PRL and thyroid hormones is discussed. The data obtained dictate the need to study the characteristics of the ratio of the levels of these hormones before the start of antipsychotic therapy (AT) in order to detect hypothyroidism and HP early, as well as to prevent the development of these hormonal dysfunctions in the process of AT and confirm the need to assess the levels of PRL and HPT-axis hormones in patients with FPE and CS before the start of the appointment of AT.
期刊介绍：
Neurochemical Journal (Neirokhimiya) provides a source for the communication of the latest findings in all areas of contemporary neurochemistry and other fields of relevance (including molecular biology, biochemistry, physiology, neuroimmunology, pharmacology) in an afford to expand our understanding of the functions of the nervous system. The journal presents papers on functional neurochemistry, nervous system receptors, neurotransmitters, myelin, chromaffin granules and other components of the nervous system, as well as neurophysiological and clinical aspects, behavioral reactions, etc. Relevant topics include structure and function of the nervous system proteins, neuropeptides, nucleic acids, nucleotides, lipids, and other biologically active components.
The journal is devoted to the rapid publication of regular papers containing the results of original research, reviews highlighting major developments in neurochemistry, short communications, new experimental studies that use neurochemical methodology, descriptions of new methods of value for neurochemistry, theoretical material suggesting novel principles and approaches to neurochemical problems, presentations of new hypotheses and significant findings, discussions, chronicles of congresses, meetings, and conferences with short presentations of the most sensational and timely reports, information on the activity of the Russian and International Neurochemical Societies, as well as advertisements of reagents and equipment.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
